C51细胞

C51是源自BALB/c实验小鼠的小鼠结肠癌细胞系，目前应用于多项不同类别的研究。

科研用途[编辑]

2003年，有学者将重组腺病毒AdEndo注射至C51细胞模型，发现内皮抑素（英语：Endostatin）在某些肿瘤细胞系中发挥直接的抗癌作用，期望内皮抑素可应用于某些结肠癌的治疗^[1]。2015年，有学者发现放射线疗法与抗体融合蛋白L19-IL2结合的治疗，可产生持久及高度协同的针对原发性C51细胞的作用，治愈率为百分之七十五^[2]。2018年，有研究指出经辐照的C51肿瘤细胞和未经辐照的CT26肿瘤细胞，具有共同的肿瘤特异性抗原（英语：Tumor antigen）。来自其他来源的继发性肿瘤可能共享更少数量的抗原，并且对C51细胞引起的严重应答反应较少^[3]

参考资料[编辑]

^ Dkhissi, F; Lu, H; Soria, C; Opolon, P; Griscelli, F; Liu, H; Khattar, P; Mishal, Z; Perricaudet, M; Li, H. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells.. Human gene therapy. 2003-07-01, 14 (10): 997–1008 [2019-12-14]. PMID 12869217. doi:10.1089/104303403766682250.
^ Zegers, CM; Rekers, NH; Quaden, DH; Lieuwes, NG; Yaromina, A; Germeraad, WT; Wieten, L; Biessen, EA; Boon, L; Neri, D; Troost, EG; Dubois, LJ; Lambin, P. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015-03-01, 21 (5): 1151–60 [2019-12-14]. PMID 25552483. doi:10.1158/1078-0432.CCR-14-2676.
^ Rekers, NH; Olivo Pimentel, V; Yaromina, A; Lieuwes, NG; Biemans, R; Zegers, CML; Germeraad, WTV; Van Limbergen, EJ; Neri, D; Dubois, LJ; Lambin, P. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.. Oncoimmunology. 2018, 7 (4): e1414119 [2019-12-14]. PMID 29632732. doi:10.1080/2162402X.2017.1414119.

[1] Dkhissi, F; Lu, H; Soria, C; Opolon, P; Griscelli, F; Liu, H; Khattar, P; Mishal, Z; Perricaudet, M; Li, H. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells.. Human gene therapy. 2003-07-01, 14 (10): 997–1008 [2019-12-14]. PMID 12869217. doi:10.1089/104303403766682250.

[2] Zegers, CM; Rekers, NH; Quaden, DH; Lieuwes, NG; Yaromina, A; Germeraad, WT; Wieten, L; Biessen, EA; Boon, L; Neri, D; Troost, EG; Dubois, LJ; Lambin, P. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015-03-01, 21 (5): 1151–60 [2019-12-14]. PMID 25552483. doi:10.1158/1078-0432.CCR-14-2676.

[3] Rekers, NH; Olivo Pimentel, V; Yaromina, A; Lieuwes, NG; Biemans, R; Zegers, CML; Germeraad, WTV; Van Limbergen, EJ; Neri, D; Dubois, LJ; Lambin, P. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.. Oncoimmunology. 2018, 7 (4): e1414119 [2019-12-14]. PMID 29632732. doi:10.1080/2162402X.2017.1414119.

[1]

[2]

[3]